Literature DB >> 19922499

Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help.

S Heidt1, D L Roelen, C Eijsink, M Eikmans, C van Kooten, F H J Claas, A Mulder.   

Abstract

In general, humoral immune responses depend critically upon T cell help. In transplantation, prevention or treatment of humoral rejection therefore require drugs that ideally inhibit both B cell and T helper cell activity. Here, we studied the effects of commonly used immunosuppressive drugs [tacrolimus, cyclosporin, mycophenolic acid (MPA) and rapamycin] on T cell helper activity and on T cell-dependent B cell responses. T cells were activated polyclonally in the presence of immunosuppressive drugs in order to analyse the effect of these drugs on T cell proliferation, co-stimulatory ligand expression and cytokines. The impact of immunosuppressive drugs on T cell-dependent immunoglobulin production by B cells was addressed in T-B cell co-cultures. All drugs affected T cell proliferation and attenuated T cell co-stimulatory ligand (CD154 and CD278) expression when T cells were activated polyclonally. Tacrolimus, cyclosporin and rapamycin also attenuated B cell stimulatory cytokine mRNA levels in T cells. As a consequence, a decrease in immunoglobulin levels was observed in autologous T-B cell co-cultures, where T cell help is essential for immunoglobulin production. In contrast, when pre-activated T cells were used to stimulate autologous B cells, calcineurin inhibitors failed to inhibit B cell immunoglobulin production, whereas MPA and rapamycin did show inhibition. From these studies, it is evident that calcineurin inhibitors affect the humoral immune response by interfering with T helper signals, but not by targeting B cells directly. Furthermore, our studies support the necessity of intervening in T cell helper function to attenuate humoral responses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19922499      PMCID: PMC2810388          DOI: 10.1111/j.1365-2249.2009.04051.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

1.  Plasma vs whole blood for therapeutic drug monitoring of patients receiving FK 506 for immunosuppression.

Authors:  M Winkler; B Ringe; J Baumann; M Loss; K Wonigeit; R Pichlmayr
Journal:  Clin Chem       Date:  1994-12       Impact factor: 8.327

2.  Distribution and protein binding of FK506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes.

Authors:  K Nagase; K Iwasaki; K Nozaki; K Noda
Journal:  J Pharm Pharmacol       Date:  1994-02       Impact factor: 3.765

Review 3.  Chronic renal allograft rejection: pathophysiologic considerations.

Authors:  Simone A Joosten; Yvo W J Sijpkens; Cees van Kooten; Leendert C Paul
Journal:  Kidney Int       Date:  2005-07       Impact factor: 10.612

4.  The effects of immunosuppressive agents on in vitro production of human immunoglobulins.

Authors:  C Stevens; N Lempert; B M Freed
Journal:  Transplantation       Date:  1991-06       Impact factor: 4.939

5.  Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation.

Authors:  M Ibernón; S Gil-Vernet; M Carrera; D Serón; F Moreso; O Bestard; J M Cruzado; J M Grinyó
Journal:  Transplant Proc       Date:  2005-11       Impact factor: 1.066

6.  Two levels of help for B cell alloantibody production.

Authors:  D J Steele; T M Laufer; S T Smiley; Y Ando; M J Grusby; L H Glimcher; H Auchincloss
Journal:  J Exp Med       Date:  1996-02-01       Impact factor: 14.307

7.  Evidence for a critical role for IL-2 in CD40-mediated activation of naive B cells by primary CD4 T cells.

Authors:  C Johnson-Léger; J R Christenson; M Holman; G G Klaus
Journal:  J Immunol       Date:  1998-11-01       Impact factor: 5.422

8.  FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects.

Authors:  L Bäckman; M Nicar; M Levy; D Distant; C Eisenstein; T Renard; R Goldstein; B Husberg; T A Gonwa; G Klintmalm
Journal:  Transplantation       Date:  1994-02-27       Impact factor: 4.939

Review 9.  The mechanism of action of FK-506 and cyclosporin A.

Authors:  G Wiederrecht; E Lam; S Hung; M Martin; N Sigal
Journal:  Ann N Y Acad Sci       Date:  1993-11-30       Impact factor: 5.691

10.  The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome.

Authors:  A Aruffo; M Farrington; D Hollenbaugh; X Li; A Milatovich; S Nonoyama; J Bajorath; L S Grosmaire; R Stenkamp; M Neubauer
Journal:  Cell       Date:  1993-01-29       Impact factor: 41.582

View more
  54 in total

Review 1.  Effect of Immunosuppressive Drugs on Humoral Allosensitization after Kidney Transplant.

Authors:  Olivier Thaunat; Alice Koenig; Claire Leibler; Philippe Grimbert
Journal:  J Am Soc Nephrol       Date:  2016-02-12       Impact factor: 10.121

Review 2.  The Contribution of B Cells in Autoimmune Liver Diseases.

Authors:  Sarah A Taylor; David N Assis; Cara L Mack
Journal:  Semin Liver Dis       Date:  2019-06-21       Impact factor: 6.115

Review 3.  Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes.

Authors:  Bart O Roep; Mark Peakman
Journal:  Nat Rev Immunol       Date:  2010-02       Impact factor: 53.106

Review 4.  Is it time to give up with calcineurin inhibitors in kidney transplantation?

Authors:  Maurizio Salvadori; Elisabetta Bertoni
Journal:  World J Transplant       Date:  2013-06-24

Review 5.  Immunology of idiopathic nephrotic syndrome.

Authors:  Manuela Colucci; Giorgia Corpetti; Francesco Emma; Marina Vivarelli
Journal:  Pediatr Nephrol       Date:  2017-04-27       Impact factor: 3.714

6.  In human cell cultures, everolimus is inferior to tacrolimus in inhibiting cellular alloimmunity, but equally effective as regards humoral alloimmunity.

Authors:  Theodoros Eleftheriadis; Georgios Pissas; Maria Sounidaki; Georgia Antoniadi; Nikolaos Antoniadis; Vassilios Liakopoulos; Ioannis Stefanidis
Journal:  Int Urol Nephrol       Date:  2017-05-15       Impact factor: 2.370

Review 7.  Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation.

Authors:  Antonio Cuadrado; David San Segundo; Marcos López-Hoyos; Javier Crespo; Emilio Fábrega
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

Review 8.  Efficacy and cytokine modulating effects of tacrolimus in systemic lupus erythematosus: a review.

Authors:  Kam Hon Yoon
Journal:  J Biomed Biotechnol       Date:  2010-06-28

9.  Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica.

Authors:  Takashi Kageyama; Mika Komori; Katsuichi Miyamoto; Akihiko Ozaki; Toshihiko Suenaga; Ryosuke Takahashi; Susumu Kusunoki; Sadayuki Matsumoto; Takayuki Kondo
Journal:  J Neurol       Date:  2012-10-18       Impact factor: 4.849

10.  Antibody-suppressor CD8+ T Cells Require CXCR5.

Authors:  Jason M Zimmerer; Bryce A Ringwald; Steven M Elzein; Christina L Avila; Robert T Warren; Mahmoud Abdel-Rasoul; Ginny L Bumgardner
Journal:  Transplantation       Date:  2019-09       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.